Molecular mechanisms of bortezomib resistant adenocarcinoma cells

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Suzuki, Erika ^a   Demo, Susan ^a   Deu, Edgar ^b   Keats, Jonathan ^c   Arastu Kapur, Shirin ^a   Bergsagel, P Leif ^d   Bennett, Mark K ^a   Kirk, Christopher J ^a  

^a ONYX PHARMACEUTICALS   (United States)

^b STANFORD UNIVERSITY   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BORTEZOMIB; CARFILZOMIB; CYCLOHEXIMIDE; CYSTEINE; IMMUNOPROTEASOME; PHENYLALANINE; PROTEASOME; PROTEASOME BETA5 SUBUNIT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER RESISTANCE; CELL CLONE; CELL STRAIN HT29; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME METABOLISM; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; MULTIPLE MYELOMA; DRUG RESISTANCE; HUMAN; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PYRAZINES;

EID: 84055182497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027996     Document Type: Article

References (37)

1. Ciechanover A, (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6: 79-87.
2. Murata S, Yashiroda H, Tanaka K, (2009) Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 10: 104-115.
3. McConkey DJ, Zhu K, (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11: 164-179.
4. Adams J, (2002) Development of the proteasome inhibitor PS-341. Oncologist 7: 9-16.
5. Bennett MK, Kirk CJ, (2008) Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 11: 616-625.
6. Dick LR, Fleming PE, (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15: 243-249.
7. Kumar S, Rajkumar SV, (2008) Many facets of bortezomib resistance/susceptibility. Blood 112: 2177-2178.
8. Shah JJ, Orlowski RZ, (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23: 1964-1979.
9. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, et al. (2007) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109: 3177-3188.
10. Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, et al. (2007) Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21: 84-92.
11. Lu S, Chen Z, Yang J, Chen L, Gong S, et al. (2008) Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 36: 1278-1284.
12. Lu S, Yang J, Song X, Gong S, Zhou H, et al. (2008) Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 326: 423-431.
13. Lu S, Yang J, Chen Z, Gong S, Zhou H, et al. (2009) Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol 37: 831-837.
14. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van ZI, et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499.
15. Ruckrich T, Kraus M, Gogel J, Beck A, Ovaa H, et al. (2009) Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23: 1098-1105.
16. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, et al. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114: 3439-3447.
17. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van ZI, et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499.
18. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, et al. (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113: 3040-3049.
19. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, et al. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24: 1506-1512.
20. Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, et al. (2006) No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res 30: 240-241.
21. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67: 6383-6391.
22. Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, et al. (2007) Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21: 84-92.
23. Groll M, Berkers CR, Ploegh HL, Ovaa H, (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14: 451-456.
24. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, et al. (2011) Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res.
25. Doherty MK, Hammond DE, Clague MJ, Gaskell SJ, Beynon RJ, (2009) Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res 8: 104-112.
26. Klare N, Seeger M, Janek K, Jungblut PR, Dahlmann B, (2007) Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation. J Mol Biol 373: 1-10.
27. Busse A, Kraus M, Na IK, Rietz A, Scheibenbogen C, et al. (2008) Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 112: 659-670.
28. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, et al. (2003) The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 278: 35869-35877.
29. Arendt CS, Hochstrasser M, (1999) Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly. EMBO J 18: 3575-3585.
30. Jager S, Groll M, Huber R, Wolf DH, Heinemeyer W, (1999) Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J Mol Biol 291: 997-1013.
31. Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, et al. (2008) Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res 14: 3503-3513.
32. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, et al. (2006) Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 134: 145-156.
33. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, et al. (2003) Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63: 6174-6177.
34. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, et al. (2011) Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). ASH 2010.
35. Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, et al. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115: 4478-4487.
36. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, et al. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110: 3281-3290.
37. Groll M, Kim KB, Kairies N, Huber R, Crews CM, (2000) Crystal Structure of Epoxomicin:20S Proteasome Reveals a Molecular Basis for Selectivity of a′ b′- Epoxyketone Proteasome Inhibitors. J Am Chem Soc 122: 1237-1238.